



LUNG CANCER
POLICY NETWORK



Contact the Network secretariat at
networksecretariat@hpolicy.com
if you are interested in joining as a
member or funder.



From evidence to action

2024 in review

Contents

Foreword

The Network in 2024

The year in numbers

2024 at a glance

Network activities in 2024

Creating a common voice for policy change

Maximising the impact of Network outputs

Strengthening the evidence base

Looking forward to 2025

Appendix: About the Network

References

3

4

6

8

10

12

16

18

24

26

30

Foreword

Of all cancers, lung cancer is the most commonly diagnosed and accounts for one in five cancer-related deaths. Recognising the huge burden the disease places on people, health systems and society, the Lung Cancer Policy Network was established in 2021 with a vision of a world where lung cancer is eliminated as a cause of death, and a mission to advance its political prioritisation.

Since its inception, the Network has become a trusted global voice. We now have 82 members from 34 countries, including 21 organisations and 7 industry partners. We have produced consensus-driven policy recommendations and evidence-based resources that help policymakers prioritise lung cancer screening, earlier detection and care pathways.

During the past year, our advocacy activities have contributed to increased attention on lung cancer. We’ve continued to use evidence to build awareness of lung cancer and develop tangible recommendations that drive real policy change.

In the years ahead, we hope to further amplify our voice and expand our reach. We look forward to welcoming more advocates and experts from around the world – and to broadening our collective expertise and experience as we work towards eradicating lung cancer.

*The Lung Cancer Policy Network
Steering Committee* ➤

The Lung Cancer Policy Network’s vision is a world where lung cancer is eliminated as a cause of death, and its mission is to advance its political prioritisation.



The Network in 2024

The Lung Cancer Policy Network is a multidisciplinary global alliance dedicated to advancing political commitment to improve lung cancer care and outcomes. We achieve this by developing evidence-informed policy recommendations, building consensus and providing a forum for shared learning.

In 2023, the Network focused on building an extensive evidence base to highlight the need to make lung cancer a global policy priority.



‘The Network is the most important and powerful pressure group for the implementation of lung cancer screening worldwide.’

HANS-ULRICH KAUCZOR
Network member, Germany



‘The Network creates positive and deliberate evidence-based efforts to reduce the impact of lung cancer around the world.’

ELLA KAZEROONI
Network member, US



‘Collaborations like the Network are essential. Together we can do much more for our patients.’

LUIS RAEZ
Network member, US



‘The Network is a broad, impartial and inclusive organisation with a wealth of experience and resources, and a clear mandate.’

HERBERT LOONG
Network member, Hong Kong

In 2024, our goal was to use this evidence base to engage policymakers and drive further action on lung cancer. Working closely with advocates to advance our messages and policy aims, we have:



created a common voice for change



expanded the reach of our outputs



strengthened the evidence base on how to improve survival rates for those living with the disease.



The year in numbers

Grew to **82** MEMBERS including **21** ORGANISATIONS representing **34** COUNTRIES

Welcomed **2** ADDITIONAL INDUSTRY PARTNERS

Had our work mentioned on **38** OCCASIONS IN *ONCODAILY*

Participated in discussions at **15** EVENTS

and had abstracts accepted for **5** CONFERENCES

Developed mutual membership with the **STRENGTHENING THE SCREENING OF LUNG CANCER IN EUROPE (SOLACE) CONSORTIUM**

Reached over **13k** PEOPLE THROUGH OUR WEBSITE

Welcomed an extra **608** (↑126%) FOLLOWERS ON LINKEDIN

Increased followers by **20.5%** ON X (TWITTER)

Held **5** NETWORK MEETINGS

including **A MEMBERS' WORKSHOP** and **AN IN-PERSON MEETING AT THE WORLD CONFERENCE ON LUNG CANCER**

These events offered an opportunity to share knowledge and build consensus

Published **13** BLOGS

including **4** CASE STUDIES FOR LUNG CANCER SCREENING

and **3** MEMBER PROFILES



'The Network offers the possibility to learn and share knowledge so other people understand the need for action.'

JOANNA BIDZIŃSKA
Network member, Poland



'I've been impressed with the Network's productivity in addressing key issues with lung cancer-specific goals and outcomes in mind.'

JOELLE FATHI
Network member, US



2024 at a glance

FEBRUARY



The Network takes part in a panel discussion exploring the future of imaging-based screening programmes as part of Cancer Care Day at the European Congress of Radiology

MARCH



The Network joins the European Lung Cancer Congress to present a poster on the screening implementation framework and supporting toolkit



Virtual Network hub launches as a forum for sharing, discussing and learning about lung cancer



NHS England rolls out a new trial focusing on people at risk of lung cancer, to identify key genetic drivers through blood tests¹

APRIL



Lung cancer screening: learning from implementation policy report is published in Arabic, French, Spanish and Simplified Chinese >



SOLACE invites the Network to join its first in-person stakeholder group meeting



The Network participates in panel discussions on global implementation and screening equity as part of the first Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment Conference, and the 45th International Conference on Screening for Lung Cancer

MAY



Roundtable brings together experts and policymakers to generate actions for policy change for lung cancer screening in Central and Eastern Europe. The Network subsequently publishes screening recommendations for the region >



The screening implementation toolkit expands to focus on underserved communities >



Implementation policy briefs are published in Arabic, French, Simplified Chinese and Spanish >



The Network joins global experts to share insights and discuss next steps for screening in Croatia as part of the event 'Early detection of lung cancer: state of the art and future developments'



The Network contributes to the methodology for the Saving Lives from Lung Cancer platform, which highlights the benefits of earlier detection >

JUNE



Network recommendations for lung cancer care pathways are presented at the European Health Management Conference >



The Network submits a response to the World Health Organization consultation on 'Best Buys' for non-communicable diseases

JULY



The German government allows the use of radiation for lung cancer screening, paving the way for a national programme²



The Network hosts a webinar: 'Care pathways for lung cancer: how can they help build a foundation for optimal care?' >

AUGUST



The Network launches policy engagement resources to support the lung cancer community to advocate for lung cancer as a policy priority >

SEPTEMBER



Malaysia announces its first AI-identified lung cancer case³



The Network participates in the International Association for the Study of Lung Cancer (IASLC) CT Screening Symposium, speaking about equity in screening, and presents four posters at the World Conference on Lung Cancer



The Network presents recommendations for the earlier detection of lung cancer at the European Society of Medical Oncology Congress



The Network joins discussions on global priorities for prevention, early detection and care pathways at the World Cancer Congress, and presents a poster on care pathways for lung cancer



The International Agency for Research on Cancer announces that the next volume of its *Handbook of Cancer Prevention* will focus on lung cancer screening⁴

OCTOBER



The Network collaborates with the Asia Pacific Coalition Against Lung Cancer (APCLC) on a webinar about screening activity in the region, as well as an in-person workshop at the Asia Conference on Lung Cancer about advancing cancer screening in the Asia-Pacific region >



Government Gazette invites the Network to contribute to a special issue on lung cancer >



The Network presents four posters at the Rescue Lung Society Conference



A new pilot for lung cancer screening launches in Ireland⁵

NOVEMBER



The Network's framework is used to inform the policy brief *Advancing Lung Cancer Screening in the Middle East and Africa: A Call for National Programmes*⁶



The Network hosts a webinar: 'Detecting lung cancer earlier: the need for effective national strategies' >



The Network publishes the report *Enhancing the earlier detection of lung cancer: effective management of incidental pulmonary nodules* >



Network activities in 2024

Creating a common voice for policy change >

Maximising the impact of Network outputs >

Strengthening the evidence base >



‘The collective knowledge, resources and shared mission empower us to drive meaningful change and improve patient outcomes.’

KORINA PATELI-BELL
Network member, Greece



‘I’m impressed by how the Network has turned solid evidence into real-world action, making a real impact in lung cancer care.’

ZHANDOS AMANKULOV
Network member, Kazakhstan



‘The Network provides a great platform to facilitate global collaborations that can create impactful change in patient care through policy initiatives underpinned by effective communication and exchange of ideas and best practices.’

ANAND SACHITHANANDAN
Network member, Malaysia



‘The most important and most influential people in lung cancer screening from all over the world are part of the Network.’

WITOLD RZYMAN
Network member, Poland



‘Being a member of the Network gives me a broad and updated view of the progress in implementation and novel achievements regarding low dose CT-based lung cancer screening. This information is very useful for our research work on screening-related multimodal biomarkers.’

LUIS MONTUENGA
Network member, Spain



Creating a common voice for policy change

The Network works with, and is embedded in, the lung cancer community. In 2024, as we became more established and further increased our membership, our goal was to amplify our policy impact by creating a common voice to guide change. To achieve this, we:

- enabled involving policymakers by developing a blueprint for local policy engagement events
- created tools that support advocates in making the case for action on lung cancer
- fostered opportunities for consensus-building by hosting events and meetings that allowed Network members to collaborate.



The Network hosted a policy roundtable in Warsaw, Poland. At the event, leading figures generated policy recommendations on implementing low-dose computed tomography (LDCT) > screening in Central and Eastern Europe.

Participants discussed the status of screening programmes in the region. They also provided insights so other countries could understand the factors that may help or hinder when implementing their own screening programmes.



‘Participation in the Lung Cancer Policy Network has enabled the lung cancer screening team in Croatia to gain valuable insights from international experts, enhancing the programme’s effectiveness. Additionally, it has provided a platform to showcase Croatia’s advances in early detection, fostering collaboration and shared learning in the global lung cancer community.’

MIROSLAV SAMARŽIJA
Network member, Croatia



‘The roundtable for Central and Eastern Europe lung cancer policy – along with the recommendations and the Network’s presence at the event – brought the essence of lung cancer screening closer to politicians.’


JOANNA BIDZIŃSKA
Network member, Poland



‘It is so important to have a multi-stakeholder network that, through collaboration, can be the united voice for change so we can really make a difference.’

MEREL HENNINK
Steering Committee member, the Netherlands

To help lung cancer advocates communicate effectively with policymakers, we launched a series of policy engagement resources, including summaries of our core reports, ➤ to help policymakers quickly grasp the key issues and understand what can be done to address them, and answers to frequently asked questions about lung cancer. ➤ As part of these resources, the Network published downloadable figures showing key data from our three seminal reports. ➤



Groups in the Middle East and Africa, and Kazakhstan, used the Network's implementation framework ➤ to inform their screening plans.



'The screening framework has made a big impact by helping countries like mine establish effective screening programmes. Looking ahead, I believe expanding access to these programmes, especially in underserved areas, will have a huge effect by enabling early detection and improving survival rates on a larger scale.'

ZHANDOS AMANKULOV
Network member, Kazakhstan

The Network has contributed to policy consultations, including the World Health Organization's 'Best Buys', and other recommended interventions for the prevention and control of non-communicable diseases.

The lung cancer community increasingly recognises the Network as a key voice in the space, and we were asked to share our recommendations and insights at events including the International Early Lung Cancer Action Program, the European Congress of Radiology, the World Cancer Congress, the Rescue Lung Society, and the IASLC CT Screening Symposium at the World Conference on Lung Cancer.



Maximising the impact of Network outputs

In 2024, we focused on extending our reach by increasing the dissemination and accessibility of our outputs to a global audience. This involved presenting our reports at webinars and conferences, as well as translating resources into languages other than English.

Our translations of the *Learning from implementation report* and the *six implementation policy briefs* expanded their reach and usability. For example, the Arabic version of the report was shared with the group Women for Oncology–Egypt.

To highlight the essential role of pathways in delivering best-practice care, we showcased the report *Care pathways for lung cancer: building a foundation for optimal care* at the European Health Management Association Conference.

Through *blog posts*, we have provided more detailed commentary on key topics, such as screening eligibility and risk factors for cancer, building our work in earlier detection and care pathways.

Presented

9

POSTERS AT CONFERENCES around the world

We also collaborated with our expert members to present nine posters at conferences including the European Lung Cancer Congress, the World Conference on Lung Cancer, and the Rescue Lung Society Conference. This brought our insights and recommendations to new audiences and increased awareness of our messages to support advocates and experts. Poster topics included:

- The Network’s interactive map of lung cancer screening research and policy activity
- Care pathways for lung cancer
- Increasing the earlier detection of lung cancer
- The Network’s framework and toolkit to support the implementation of LDCT screening, with a focus on the inclusion of underserved communities
- Evidence-based communication on lung cancer screening for policymakers.



‘The more visible we are as a Network, the more light is shed on this medically and socially relevant issue.’

MARIUSZ ADAMEK

Steering Committee member, Poland



‘I am using Network resources with graduate students at the Medical University of Gdańsk.’

JOANNA BIDZIŃSKA

Network member, Poland






Strengthening the evidence base

Building on our work from 2023, we expanded our analysis to offer detailed recommendations in our key focus areas. This helps ensure that our vast evidence base for action, coupled with our policy recommendations, will continue to be at the forefront of decision-making, and support implementation around the world.

The interactive map was updated throughout 2024 to showcase additional clinical trials, implementation studies and

organised LDCT screening programmes. The map was cited in ‘Risk-based lung cancer screening performance in a universal healthcare setting’, an article in *Nature Medicine*, as well as in ‘Current and Future Perspectives on Computed Tomography Screening for Lung Cancer: A Roadmap From 2023 to 2027’, an article written by members of IASLC in the *Journal of Thoracic Oncology*.^{7,8} The tool was also included in conference presentations by lung cancer experts.



‘The Network is doing great work! I have gone to the website for umpteen resources, which are well developed and truly exemplary.’

SEWANTI LIMAYE
Network member, India



4

CASE STUDIES

were published to supplement the map by providing a more in-depth look at examples.

In 2024, the map was used:



by
1,897
VISITORS (3,792 TIMES)



in
78
COUNTRIES



‘The map has been useful for understanding the progress being made in lung cancer screening. It provides insights into how programmes and trials are being implemented – for example, which eligibility criteria or nodule protocols a country might be using.’

KATRINA ANDERSON
Network member, Australia



The Network has broadened the use of the screening implementation framework and toolkit by developing resources further and collaborating with key organisations. The implementation toolkit was expanded to help users consider and engage with people from traditionally underserved groups. ➤



‘Lung cancer screening doesn’t determine whether a person gets lung cancer. But if lung cancer is found in a screening programme, 75% of the time it is at an early stage and is curable.’

ANDREA BORONDY KITTS
Network Steering Committee
patient representative, US



The Network partnered with the APCLC on a webinar and workshop that focused on advancing screening in the region.

The Network’s screening implementation framework acted as the foundation for these events, and facilitated discussions on what can be done to accelerate the optimal implementation of screening.

Lung cancer screening is at varying stages across the Asia-Pacific region.

Our events allowed attendees to learn about the barriers and opportunities encountered by countries that had already implemented screening

Participants from

23
COUNTRIES

attended the webinar

and over

40
DELEGATES

attended the in-person workshop

programmes. The discussions were consolidated into a set of priority policy recommendations for the region: ➤

- improve awareness of lung cancer and the importance of earlier detection
- foster collaboration and shared learning
- initiate research on the effectiveness and cost-effectiveness of screening
- take a systems approach to large-scale screening implementation.



‘A truly collaborative effort between the Network and the APCLC resulted in a first-of-its-kind in-person policy capacity-building workshop targeting various stakeholders in Asia. This well-attended workshop allowed for the exchange of ideas, and discussions on common challenges and successes which can be taken as reference to move individual programmes forward.’

HERBERT LOONG

Steering Committee member, Hong Kong





We further explored our recommendations on care pathways and earlier detection strategies through webinars with expert speakers. These events brought together policymakers, industry representatives, patient organisations, clinicians and academics.



The webinar ‘Care pathways for lung cancer: how can they help build a foundation for optimal care?’, hosted in July, showcased the role of pathways in improving health system efficiency, and patient experiences and outcomes. ➤

The webinar was attended by people from

40
COUNTRIES



‘The webinar presented a comprehensive review of the pathways that should be followed to treat lung cancer in an efficient manner.’

MARIUSZ ADAMEK

Steering Committee member, Poland




In November, ‘Detecting lung cancer earlier: the need for effective national strategies’ highlighted the opportunity earlier detection offers in shifting diagnosis to a less advanced stage and improving rates of survival by increasing treatment options. ➤

The webinar was attended by

43
PARTICIPANTS

from

17
COUNTRIES



The Network published the report ***Enhancing the earlier detection of lung cancer: effective management of incidental pulmonary nodules***, which outlines how the management of incidental pulmonary nodules (IPNs) can be optimised. The report provides recommendations for policymakers to implement management strategies. ➤

To develop the report, the network carried out

11
EXPERT
INTERVIEWS

representing

6
COUNTRIES

and held a workshop with members to build consensus on its recommendations.



‘The new IPN material is particularly impactful on early lung cancer detection.’

ELLA KAZEROONI

Network member, US



‘The Network provides an opportunity for Cancer Australia to collaborate with other countries on initiatives such as the *Effective management of IPNs* report, and to share insights about developing and implementing lung cancer screening, such as participating in the joint webinar with the APCLC.’

KATRINA ANDERSON

Network member, Australia



Looking forward to 2025

In 2025, we will focus on extending our reach by leveraging our global expertise and respected voice. This will equip us to further advance earlier detection and lung cancer care, and maximise policy impact through collaboration.



‘We can use the outputs of the Network to support and positively affect policies related to lung cancer care in various situations in different countries.’

YEON WOOK KIM

Network member, South Korea

Appendix: About the Network

The Network was established in 2021 to encourage policymakers around the world to make improving survival from lung cancer a priority. Since its inception, the Network has been growing in size and reach. Our goal is to continue to gather consensus-driven insights to co-create impactful reports and resources.



‘Being part of the Network enables me to engage with like-minded professionals, and to receive the knowledge and resources to help shape this field.’

HERBERT LOONG
Network member,
Hong Kong



‘Being part of the Network means collaborating with great minds around the world who are aligned in the collective effort to reduce the burden of lung cancer.’

ELLA KAZEROONI
Network member, US



‘I appreciate contributing as a member of the Network and serving as a part of a collective global effort, with the belief that we can impact the lives of those at risk of, and affected by, lung cancer.’

JOELLE FATHI
Network member, US



‘One of the things that makes the Network essential is that advocates, industry and lung cancer experts are working together to improve survival.’

LUIS RAEZ
Network member, US



‘The Network allows me to connect with other members and keep up to date with cutting-edge evidence and activities worldwide.’

YEON WOOK KIM
Network member,
South Korea



‘I envisage the Network as a constant brainstorm of those who are engaged in implementing screening in their countries.’

MARIUSZ ADAMEK
Steering Committee
member, Poland



‘I enjoy the broad spectrum of inputs from all the international members.’

HANS-ULRICH KAUCZOR
Network member, Germany



‘The Network generates the opportunity to exchange ideas and generate new ones.’

GIORGIO SCAGLIOTTI
Network member, Italy



‘I am proud to be part of a community that works for change.’

ANNA KERPEL-FRONIUS
Network member, Hungary



‘The Network has tremendous potential to influence policy development globally.’

SEWANTI LIMAYE
Network member, India



‘Being part of an international and interdisciplinary Network allows me to look at the problems and challenges from a different perspective. It is the realistic opportunity to work for the good of others.’

JOANNA BIDZIŃSKA
Network member, Poland



‘We value hearing from other members about what their countries are doing in implementing lung cancer screening. We learn from their experiences and find out about the clinical and policy resources available to us.’

KATRINA ANDERSON
Network member, Australia



‘Being part of the Network means connecting with people who are just as passionate about improving lung cancer care as I am. It’s a chance to learn, share ideas, and make a real difference in early detection and patient outcomes.’

ZHANDOS AMANKULOV
Network member, Kazakhstan

Our members

The Network is global and multidisciplinary, bringing together patient advocates, clinicians, researchers and industry partners – all with expertise and experience in lung cancer. It acts as a forum for exchange and alliance-building, and offers a unique opportunity for collaboration to deliver evidence-based, consensus-driven outputs for policy engagement.

Organisation members



Individual members

Mariusz Adamek, Medical University of Silesia, Medical University of Gdańsk
Humaid Al Shamsi, Burjeel Cancer Institute
Zhandos Amankulov, Embassy of Kazakhstan
Katrina Anderson, Cancer Australia
Chunxue Bai, Zhongshan Hospital Fudan University
Anne-Marie Baird, Lung Cancer Europe
David Baldwin, University of Nottingham
Angela Barry, GO2 for Lung Cancer
Joanna Bidzińska, Medical University of Gdańsk
Torsten Gerriet Blum, Helios Klinikum Emil von Behring
Andrea Borondy Kitts, Rescue Lung Society
Mark Brooke, Lung Foundation Australia
Joanna Chorostowska-Wynimko, National Institute of Tuberculosis and Lung Disease
Lynsey Conway, UK Lung Cancer Coalition
Sébastien Couraud, Lyon Sud Hospital
Sue Crengle, University of Otago
Joelle Fathi, GO2 for Lung Cancer
John Field, University of Liverpool
Jesme Fox, Roy Castle Lung Cancer Foundation
Benjamin Gannon, Guardant Health
Pilar Garrido, University of Alcalá
David Gilligan, UK Lung Cancer Coalition
Tiffany Gowen, American College of Radiology
Derek Griffith, Global Action on Men's Health
Catharine Grimes, Bristol Myers Squibb Foundation
Vitali Grozman, Karolinska Institutet
Helen Haggart, Johnson & Johnson
Ebba Hallersjö Hult, Vision Zero Cancer
Michael Hartevelt, MSD
Joachim Hayes, Intuitive
Merel Hennink, Global Lung Cancer Coalition
Claudia Henschke, Mount Sinai Hospital
Jennifer Higgins, Guardant Health
Fred Hirsch, Mount Sinai Hospital
Hidehito Horinouchi, National Cancer Center Hospital
Hans-Ulrich Kauczor, University Hospital Heidelberg
Ella Kazerooni, University of Michigan
Karen Kelly, International Association for the Study of Lung Cancer
Anna Kerpel-Fronius, Országos Korányi Pulmonológiai Klinika
Yeon Wook Kim, Seoul National Bundang Hospital
Jennifer King, International Association for the Study of Lung Cancer
Vladimír Koblížek, Charles University
David CL Lam, University of Hong Kong

Stephen Lam, University of British Columbia
David LeDuc, AstraZeneca
Olivier Leleu, Centre Hospitalier d'Abbeville
Sewanti Limaye, Sir HN Reliance Foundation Hospital & Research Centre
Herbert Loong, Chinese University of Hong Kong
Ante Marušić, University Hospital Centre Zagreb
Jan van Meerbeeck, Antwerp University and University Hospital
Luis Montuenga, University of Navarra
Andrea Nurko, American Lung Cancer Screening Initiative
Zulfiquer Otty, Icon Cancer Centre Townsville
Matthijs Oudkerk, University of Groningen
Ugo Pastorino, Istituto Nazionale Tumori
Korina Pateli-Bell, FairLife Lung Cancer Care
Nadia Pellanda, MSD
Lauren Pretorius, Campaigning for Cancer
Luis Ræz, Memorial Cancer Institute
Nicole Rankin, University of Melbourne
Hilary Robbins, International Agency for Research on Cancer
Oluf Dimitri Røe, Aalborg University Hospital
Witold Rzyman, Medical University of Gdańsk
Anand Sachithanandan, Lung Cancer Network Malaysia
Ricardo Sales dos Santos, Propulmão
Miroslav Samaržija, University of Zagreb
Giorgio Scagliotti, University of Turin
Sebastian Schmidt, Siemens Healthineers
Victoria Schneider, Siemens Healthineers
Luis Seijo, University of Navarra
Dorith Shaham, Hadassah Medical Center
Annemiek Snoeckx, Antwerp University Hospital
Ewelina Szymtke, Lung Cancer Europe
Edyta Szurowska, Medical University of Gdańsk
Stefania Vallone, Women Against Lung Cancer in Europe
Giulia Veronesi, Vita-Salute San Raffaele University
Lucia Viola, Luis Carlos Sarmiento Angulo Cancer Treatment and Research Center
Murry Wynes, International Association for the Study of Lung Cancer
Dawei Yang, Zhongshan Hospital Fudan University
Pan-Chyr Yang, National Taiwan University
David Yankelevitz, Mount Sinai Hospital
Andrew Zebrak, Intuitive

References

1. NHS England. Thousands more lung cancer patients to get innovative blood test as part of NHS pilot. Available from: <https://www.england.nhs.uk/2024/03/thousands-more-lung-cancer-patients-to-get-innovative-blood-test-as-part-of-nhs-pilot/> [Accessed 08/11/24]

2. Deutsche Röntgengesellschaft. 2024. Breakthrough on the way to an early detection program for lung cancer [translated]. Available from: <https://www.drg.de/de-DE/10953/lungenkrebsfrueherkennung/> [Accessed 08/11/24]

3. OncoDaily. 2024. The first case of Lung Cancer detected by AI in Malaysia. Available from: <https://oncodaily.com/insight/137306> [Accessed 08/11/24]

4. International Agency for Research against Cancer. IARC Handbooks Volume 21: Lung Cancer Screening. Available from: <https://www.iarc.who.int/news-events/iarc-handbooks-volume-21-lung-cancer-screening/> [Accessed 08/11/24]

5. University of Medicine and Health Sciences. New €4.9m Beaumont RCSI Cancer Centre and Irish Cancer Society partnership to transform lung cancer care in Ireland. Available from: <https://www.rcsi.com/dublin/news-and-events/news/news-article/2024/10/new-beaumont-rcsi-cancer-centre-and-irish-cancer-society-partnership-to-transform-lung-cancer-care> [Accessed 08/11/24]

6. Lung Ambition Alliance. 2024. *Advancing Lung Cancer Screening in the Middle East and Africa: A Call for National Programmes*. Dubai: Lung Ambition Alliance

7. Tammemägi MC, Darling GE, Schmidt H, *et al.* 2024. Risk-based lung cancer screening performance in a universal healthcare setting. *Nat Med* 30(4): 1054–64

8. Lam S, Bai C, Baldwin DR, *et al.* 2024. Current and Future Perspectives on Computed Tomography Screening for Lung Cancer: A Roadmap From 2023 to 2027 From the International Association for the Study of Lung Cancer. *J Thorac Oncol* 19(1): 36–51

Funders

AstraZeneca, Bristol Myers Squibb Foundation, Guardant Health, Intuitive, Johnson & Johnson, MSD and Siemens Healthineers